Alzheimer’s Disease

Alzheimer’s disease (AD) is a neurodegenerative disease that causes progressive and disabling impairment of cognitive functions including memory and attention. Alzheimer’s disease is also characterised by neuropsychiatric symptoms like apathy, social withdrawal, disinhibition, agitation and psychosis. Later stage symptoms also include sleep disturbances and motor deficits like dystonia, akathisia and parkinsonian symptoms. AD is now the sixth leading cause of death in the United States, representing a significant unmet medical need.

At Transpharmation, our multi-faceted approach combines the use of naturally occurring deficits in aged animals along with pharmacological intervention to mimic aspects of the disease such as cognitive deficits, and sleep disruption. Furthermore, using our extensive biomarker platform we can profile translational disease markers such as TAU/phospho-TAU in both rodent and human tissue (via our CNS biobank) and assess the role of neuroinflammatory markers, such as cytokines, chemokines and microglia in AD disease pathology.

Examples of the models we offer include:

pain1This list is not exhaustive, we are always developing new areas of discovery within our preclinical field of expertise. If there is something particular that is not listed here please do contact us.

Start a Conversation

uk flag +44 (0)20 7691 0984

ireland flag +353 (0)1896 42 60



Copyright © 2020 Transpharmation Ltd. All Rights Reserved.

Copyright © 2019 Transpharmation Ltd. All Rights Reserved. Website created by Identity Ipswich Web Design


The first International Association for the Study of Pain, (IASP) virtual conference is live!

Come and visit Transpharmation’s booth #iaspvirtualseries

View our latest specialist poster on pain; ‘The effect of a reduced streptozocin dose and social housing on well-being, mechanical hypersensitivity and burrowing behaviour in type 1 diabetic rodents’ and find out more about our wide-ranging pain expertise.  We look forward to seeing you there.

IASP Footer

21st International Conference on AD Drug Discovery